Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1999 1
2000 1
2002 2
2003 1
2004 3
2005 4
2006 4
2007 5
2008 6
2009 3
2010 10
2011 6
2012 7
2013 11
2014 14
2015 10
2016 16
2017 18
2018 19
2019 16
2020 17
2021 16
2022 12
2023 18
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Grijpink-Ongering LG, Gonzalez M, Jóźwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, Scolyer RA, Boekhout AH, Long GV, Blank CU. Reijers ILM, et al. Among authors: jozwiak k. Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. Nat Med. 2022. PMID: 35661157 Clinical Trial.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT investigators. Harbeck N, et al. Among authors: jozwiak k. J Clin Oncol. 2023 Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. J Clin Oncol. 2023. PMID: 36809046 Clinical Trial.
Response to Klar and Adams.
Dackus GMHE, Jóźwiak K, Hauptmann M, Linn SC. Dackus GMHE, et al. Among authors: jozwiak k. J Natl Cancer Inst. 2022 Jan 11;114(1):167-168. doi: 10.1093/jnci/djab153. J Natl Cancer Inst. 2022. PMID: 34396390 Free PMC article. No abstract available.
Isothermal titration calorimetry in membrane protein research.
Draczkowski P, Matosiuk D, Jozwiak K. Draczkowski P, et al. Among authors: jozwiak k. J Pharm Biomed Anal. 2014 Jan;87:313-25. doi: 10.1016/j.jpba.2013.09.003. Epub 2013 Sep 18. J Pharm Biomed Anal. 2014. PMID: 24119484 Review.
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jóźwiak K, Zu Eulenburg C, Kreipe HH, Harbeck N; ADAPT TN investigators. Gluz O, et al. Among authors: jozwiak k. Clin Cancer Res. 2022 Nov 14;28(22):4995-5003. doi: 10.1158/1078-0432.CCR-22-0482. Clin Cancer Res. 2022. PMID: 35797219
Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye.
Zarnowski T, Tulidowicz-Bielak M, Zarnowska I, Mitosek-Szewczyk K, Wnorowski A, Jozwiak K, Gasior M, Turski WA. Zarnowski T, et al. Among authors: jozwiak k. Curr Med Chem. 2017;24(32):3547-3558. doi: 10.2174/0929867324666170509120257. Curr Med Chem. 2017. PMID: 28486923 Review.
Association of body mass index and long-term mortality in patients from nationwide LIPIDOGRAM 2004-2015 cohort studies: no obesity paradox?
Osadnik T, Nowak D, Osadnik K, Gierlotka M, Windak A, Tomasik T, Mastej M, Łabuz-Roszak B, Jóźwiak K, Lip GYH, Mikhailidis DP, Toth PP, Sattar N, Goławski M, Jóźwiak J, Banach M; LIPIDOGRAM Investigators. Osadnik T, et al. Among authors: jozwiak k. Cardiovasc Diabetol. 2023 Nov 28;22(1):323. doi: 10.1186/s12933-023-02059-0. Cardiovasc Diabetol. 2023. PMID: 38017465 Free PMC article.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jóźwiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: jozwiak k. Ann Oncol. 2023 Jun;34(6):531-542. doi: 10.1016/j.annonc.2023.04.002. Epub 2023 Apr 14. Ann Oncol. 2023. PMID: 37062416 Free article. Clinical Trial.
206 results